The first fixed-dose combination of the ACT artesunate-amodiaquine (ASAQ), developed by DNDi and Sanofi and branded ASAQ Winthrop®, was prequalified by WHO in 2008. As one of five ACTs recommended by WHO for the treatment of uncomplicated malaria, ASAQ has played an important role in the global effort to improve timely access to treatment.
The product is administered once per day, for 3 days duration. ASAQ Winthrop has been approved in 33 countries and over 537 million treatments distributed since 2007. In general, ASAQ is the lowest-priced of the fixed-dose ACT combinations procured by the Global Fund and public-sector procurement partners.
Through an agreement with DNDi in 2015, MMV agreed to take over access stewardship of ASAQ, supporting use per its recommended label, and helping disseminate evidence-based information regarding product efficacy and safety for consideration by national treatment programmes in line with WHO’s guidance.